ABSTRACTObjectives: No long-term clinical efficacy and safety study of resveratrol as adjuvant therapy along with gold standard therapy has been conductedin patients with essential hypertension. The aim of this study was to investigate the efficacy and safety of resveratrol as an adjuvant therapy in newlydiagnosed hypertensive patients.Methods: In this randomized active-controlled study, hypertensive patients (male/female) of 20-65 years aged were randomized (1:1) to receivetelmisartan 20 mg or telmisartan 20 mg plus resveratrol 1 g daily for 12 months. Efficacy variables included a change in systolic and diastolic bloodpressure (DBP) from baseline and were followed up for every 3 months. Treatment-emergent adverse events were assessed.Results: A total of 60 hypertensive patients were analyzed (telmisartan [n=30] and telmisartan plus resveratrol [n=30]). Resveratrol as an adjuvantwith telmisartan significantly reduced in systolic (p<0.001) and DBP (p<0.001) as compared to telmisartan monotherapy. Change in systolic and DBPfrom baseline was significantly higher in telmisartan plus resveratrol group than telmisartan (p<0.001) at all followed visits. Both the study drugshave similar safety profile and found well tolerable.Conclusions: Resveratrol plus Telmisartan was found to be superior over telmisartan monotherapy in reducing systolic and DBP in newly diagnosedhypertensive patients. Both the study drugs were effective with comparable safety profile. Our study supports the long-term clinical efficacy andsafety study of resveratrol along with gold standard therapy in essential hypertension.Keywords: Essential hypertension, Resveratrol, Systolic and diastolic blood pressure, Telmisartan.
Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis
